Blood

Blood is published by American Society of Hematology and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research and Lymphoma Diagnosis and Treatment, together about 26.4% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)

Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well-organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to submit a presubmission inquiry if they are uncertain whether their work falls within the general scope of the journal.Blood has formulated more precise scopes for immunobiology and immunotherapy, vascular biology, HIV/HTLV, and clinical trial submissions. The journal is very interested in submissions as reflected in the definitions linked below.Immunobiology and Immunotherapy scopeVascular Biology scopeHIV/HTLV scopeClinical Trials scopeBlood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.Papers felt to be outside the scope of Blood will be returned to the author without full peer review.

From the journal's Aims & Scope

Research area (LetPub): Hematology

Editor-in-chief Andrew RobertsPublisher website

Editorial board by country: none in mainland China; most named United States 62, United Kingdom 12, Australia 11, Canada 9, Germany 8 (131 members with a country) Editorial board ↗Publisher website · 2026-10-01

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

22.85LetPub · 2026-09-13

Impact factor (publisher)

23.9Publisher website · 2026-10-01

CiteScore 2026-06

22.8LetPub · 2026-09-13

CiteScore (publisher)

22.8Publisher website · 2026-10-01

SJR 2026-06

5.91LetPub · 2026-09-13

SNIP 2026-06

3.77LetPub · 2026-09-13

h-index

426LetPub · 2026-09-13

h-index

643OpenAlex · 2026-10-01

i10-index

54,266OpenAlex · 2026-10-01

2-year mean citedness

1.58OpenAlex · 2026-10-01

Self-citation rate

5%LetPub · 2026-09-13

Share of gold OA articles

29.53%LetPub · 2026-09-13

Volume

Articles per year

491LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

about 1 monthLetPub · 2026-09-13

Average acceptance (community reports)

Fairly hardLetPub · 2026-09-13

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

American Society of Hematology

Country or region

UNITED STATES

Language

English

Frequency

Semimonthly

Founded

1946

ISSN

0006-4971

Electronic ISSN

1528-0020

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗LetPub
• Special issues ↗Publisher website